|
BRIEF-Vectura says had pre-IND meeting with FDA on asthma treatment for …
Reuters BRIEF-Vectura says had pre-IND meeting with FDA on asthma treatment for children. July 28. July 28 Vectura Group Plc. * Announces successful pre-ind meeting with US FDA regarding vr647. * Fda has agreed with our intent to rely on 505(B) pathway for … |
View full post on asthma – Google News